Pharmaceutical

Janssen’s BALVERSA receives EC approval for metastatic urothelial carcinoma

The European Commission (EC) has approved Janssen's BALVERSA as a treatment for adults with unresectable or metastatic urothelial carcinoma.

Aug 27, 2024 - 04:00
Janssen’s BALVERSA receives EC approval for metastatic urothelial carcinoma
The European Commission (EC) has approved Janssen's BALVERSA as a treatment for adults with unresectable or metastatic urothelial carcinoma.
Read the original article

Tags:

Previous Article

China NMPA grants approval for GenFleet’s fulzerasib to treat lung cancer

Next Article

Germany to Provide 100,000 Mpox Vaccine Doses to Combat Outbreak in Africa

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Nobel Prize, in a rarity, celebrates a fruitful and durable partnership

STAT+: Nobel Prize, in a rarity, celebrates a fruitful ...

Oct 2, 2023

STAT+: Pharmalittle: Appeals court rules Purdue can shield Sacklers from lawsuits; chemo shortage blamed on drugmakers’ lack of investment

STAT+: Pharmalittle: Appeals court rules Purdue can shi...

May 31, 2023

STAT+: After FDA nod, Better Therapeutics races to boost dwindling cash

STAT+: After FDA nod, Better Therapeutics races to boos...

Jul 16, 2023